Molnupiravir is not covered by the National COVID-19 Treatment Task Force, according to the ICMR

Molnupiravir is not covered by the National COVID-19 Treatment Task Force, according to the ICMR

The decision has been taken after an extensive discussion amongst national experts. Addressing media persons, Dr Bhargava said, “I think we have had an extensive debate, extensive discussion amongst national experts and we reviewed whatever data is available from the three trials such as move in, move out and move ahead trials. The move-in trial was done on 1,433 patients. The move out trial was prematurely terminated for business reasons. The move ahead trial is underway. There are 12 clinical trials registered on the Clinical Trial Registry of India which are also starting or about to start.”

The antiviral medicine Molnupiravir is not included in the National Treatment Task Force for COVID-19, according to Balram Bhargava, Director General of the Indian Council of Medical Research (ICMR). Shalini Bhardwaj contributed to this article. The antiviral medicine Molnupiravir is not included in the National Treatment Task Force for COVID-19, according to Balram Bhargava, Director General of the Indian Council of Medical Research (ICMR).

“Molnupiravir has the certain risks that warrant caution in its use. Experts present at the meeting opined that there is a rampant and irrational use of Molnupiravir. Efforts should be made to restrict its use as known and unknown harms far outweigh its claimed benefits. Currently available synthesised evidence was reviewed and the members unanimously agreed that it does not merit the inclusion of Molnupiravir in the national treatment guidelines,” explained the ICMR DG. Dr Bhargava said that emerging evidence will be constantly be reviewed and further highlighted that the current clinical window of the application appears extremely narrow for Molnupiravir with relevance only to elderly and unvaccinated patients with other comorbidities. “There was no evidence for benefit in diabetes, and those who are previously infected with COVID-19 or were vaccinated,” he added.

Dr VK Paul, Member, Niti Aayog also cleared several doubts on the usage of the antiviral drug. He said, “We discussed this atleast four times in the national task force, with our scientific committees and groups on vaccination and others. These are proactive reviews in the last meeting. We discussed about Molnupiravir and it has risks. So, there should be a cautious approach. It has been also seen that it is used irrationally. This medicine does not come under the National COVID treatment protocol. This is evolving science and will then dictate how we proceed further.”Raising concerns over its uses, Dr Paul said that Molnupiravir should not be given to patients less than 18 years of age. He also said that the drug cannot be given to pregnant women as this can lead to defects in the foetus. However, he added that the drug can reduce hospitalisation from 6 per cent to 3 per cent.

Drugs Controller General of India (DCGI) on December 28 had approved Dr Reddy’s laboratories for the emergency-use authorization to manufacture and market the oral anti-viral drug Molnupiravir capsules 200 mg for the treatment of adult patients with COVID-19, with the oxygen saturation level less than 93 per cent and who have a high risk of progression of the disease including hospitalization or death. Dr Reddy’s will be manufacturing and supplying the generic version of Molnupiravir to over 100 low and middle-income countries. The antiviral pill was recommended by the Subject Expert Committee after providing additional efficacy data by the 13 pharma companies.

Disclaimer: If you need to edit or update this news from compsmag then kindly contact us Learn more

For Latest News Follow us on Google News


Latest Headlines
  • Show all
  • Trending News
  • Popular By week
SEC Chairman Gensler Discusses How Securities Laws Apply to Crypto Tokens – Won’t Say Whether Ethereum Is a Security – Bitcoin Regulation News
SEC Chairman Gensler Discusses How Securities Laws Apply to Crypto Tokens – Won’t Say Whether Ethereum Is a Security – Bitcoin Regulation News
Our role at the SEC is to ensure that the public still gets basic protection. While acknowledging that new ways to invest, including crypto tokens and Special ...
COVID-19 was the leading cause of death among police officers in 2021, report says
COVID-19 was the leading cause of death among police officers in 2021, report says
Former Connecticut state trooper Troy Anderson told CBS News that the number of officer deaths in the line of duty deserves more attention.  Sixty-one officers ...
Infosys reports an 11.8% increase in third-quarter net income and raises its revenue growth forecast for FY22 to up to 20%
Infosys reports an 11.8% increase in third-quarter net income and raises its revenue growth forecast for FY22 to up to 20%
The Bengaluru-based company’s consolidated net profit in the September-December 2020 quarter was Rs 5,197 crore. Its revenue soared 23 per cent to Rs 31,867 ...
To compensate for the PS5 scarcity, Sony is producing extra PS4s
To compensate for the PS5 scarcity, Sony is producing extra PS4s
As well as offsetting some of the revenue loss, building more PS4 units will allow Sony to negotiate better deals with manufacturers, according to Bloomberg. ...
NFL Injury Updates, Latest League News for Wednesday, Jan 12
NFL Injury Updates, Latest League News for Wednesday, Jan 12
Fournette (hamstring) and David (foot) both went on IR on Dec. 23, with the expectation that they’d return for a playoff run. The two veterans made crucial ...
Transactions: Encompasses Health Inks Nova JV;  PHMC Affiliates with Greater Philadelphia’s VNA
Transactions: Encompasses Health Inks Nova JV; PHMC Affiliates with Greater Philadelphia’s VNA
The recently announced JV complements a joint venture between Encompass Health and the nonprofit Saint Alphonsus established in 2019. The Birmingham, ...
TPG listing caps 30 years of easy money
TPG listing caps 30 years of easy money
Register Register now for FREE unlimited access to Reuters.com TPG has focused on its bread and butter. Its prospectus boasts that its funds own 280 companies ...
Cambridge Wilkinson Investment Banking closes US$150 million litigation financing line
Cambridge Wilkinson Investment Banking closes US$150 million litigation financing line
SOURCE Cambridge Wilkinson US 1-646-582-9423 Rob Bolandian, Partner & Global Head of Investment Banking All securities assignments are completed through ...
Chinese Technology Stocks bounce like cheap valuation bait for buyers
Chinese city slack for Omicron testing shows economic problems
Some companies are already feeling the pressure as the northern port city scrambles to contain the spread of the ultra-contagious variant in the community. ...
Fire breaks out inside West Monroe business, no injuries
Fire breaks out inside West Monroe business, no injuries
Copyright 2022 KNOE. All rights reserved. It is believed by the family that there was an electrical issue that sparked the fire. No injuries have been ...
Show next
We will be happy to hear your thoughts

      Leave a reply

      Compsmag - Latest News In Tech and Business
      Logo